Supernus Pharmaceuticals SUPN Enterprise value

Enterprise value at other companies

AbbVieABBV

$460.96B+24.7%

Rapport Therapeutics, Inc.RAPP

$1.94B+375%

Acadia PharmaceuticalsACAD

$4.02B+13.2%

Axsome TherapeuticsAXSM

$8.56B+52.9%

Neurocrine BiosciencesNBIX

$13.41B+18.5%

XER

Xeris Biopharma Holdings, Inc.XERS

$1.54B+62.6%

FAQ

What is Supernus Pharmaceuticals's enterprise value?

Supernus Pharmaceuticals (SUPN) reported enterprise value of $2.83B in Q1 2026.

How has Supernus Pharmaceuticals's enterprise value changed year-over-year?

Supernus Pharmaceuticals's enterprise value increased by 62.3% year-over-year, from $1.74B to $2.83B.

What is the long-term trend for Supernus Pharmaceuticals's enterprise value?

Over 5 years (2020 to 2025), Supernus Pharmaceuticals's enterprise value has grown at a 20.1% compound annual growth rate (CAGR), from $1.1B to $2.76B.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.